The primary goal of this medication is to provide long-term therapeutic support in cardiology and vascular health. Its uses focus on managing the risk of serious, acute events in high-risk patients.

What Фазостабил Helps Manage

This medicine is applied across domains where additional symptomatic support is needed, primarily to help manage the risk of future cardiovascular and cerebrovascular events. It is relevant for preventing recurrent heart attacks, reducing the risk of a second ischemic stroke (blood clot in the brain), and providing supportive management for conditions like stable and unstable angina pectoris (chest discomfort). This assists with reducing the likelihood of a recurrent, disruptive event and supports general well-being over time.

“The long-term therapeutic support this medication provides helps patients cope more steadily with symptom fluctuations and manage their vascular health proactively.”

This supportive treatment is also a relevant component following specific procedures, such as coronary artery stenting or bypass graft surgery, where it contributes to supporting the outcome of the procedure by helping the treated vessel remain open. This assists with maintaining functional stability and comfort during symptomatic phases.

Quick Fact: Symptomatic Support Focus The medication may be part of symptomatic management for stable and unstable angina, contributing to easing the overall symptom load related to discomfort.

Official Eligibility and Contraindications

The eligibility profile for Фазостабил is strictly defined by regulatory documents, primarily due to the restrictions associated with its active antiplatelet component, Acetylsalicylic Acid (ASA).

Populations for whom use is contraindicated (Must Not Use):

• Individuals with known hypersensitivity to ASA, other salicylates, or any NSAID.
• Patients with active bleeding or a congenital or acquired hemorrhagic disorder.
• Patients with active peptic ulceration or acute gastrointestinal bleeding.
• Pregnant persons in the third trimester (starting at 30 weeks gestation).
• Children and teenagers (generally under 16) with viral infections (e.g., flu or chickenpox), due to the risk of Reye's Syndrome.

Populations Requiring Conditional or Restricted Use:

• Patients with severe renal impairment or severe hepatic impairment; use must be avoided or requires special consideration.
• Older adults (age 60 and over) have an increased risk of gastrointestinal bleeding and require careful assessment.
• Pregnancy (First/Second Trimester): Use is generally restricted to high-risk conditions, such as preeclampsia prophylaxis, under medical direction.

Age-Group Eligibility:

Routine antiplatelet use is approved for adults and adolescents generally 16 years and over for conditions like secondary cardiovascular prevention. The drug is not recommended for standard use in younger children.

Interactions with other medicines and products — official regulatory information for Фазостабил

Interaction scope

Interaction classifications (high-level)

Resulting interaction structure

Official interaction statements:

• Co-administration with Methotrexate (≥ 15 mg/week) is formally prohibited due to an officially documented risk of increased methotrexate toxicity.
• Concomitant use with Anticoagulants or SSRIs is noted to result in a pharmacodynamic enhancement of the bleeding risk.
• Systemic Glucocorticoids are officially noted to reduce the plasma concentration of Acetylsalicylic Acid (ASA) by increasing its elimination rate.

Connection to the overall interaction profile: Regulatory documents establish the interaction structure by defining formal prohibitions and mandatory timing rules, such as the required separation of Ibuprofen administration from ASA. This profile identifies categories of medicines, including NSAIDs and Anticoagulants, that pose an officially documented risk of additive bleeding or exposure modification when co-administered. The entire set of constraints is aligned with formal government-approved prescribing information.

The combined mechanism of Фазостабил is centered on irreversible enzyme inhibition and localized chemical modulation. The primary component, Acetylsalicylic Acid (ASA), acts as a permanent inhibitor of the Cyclooxygenase-1 ( COX-1) enzyme present in platelets. This is achieved by the acetylation of a serine residue within the enzyme, which prevents the conversion of arachidonic acid into pro-aggregatory mediators. The subsequent cascade halts the synthesis of Thromboxane A2 ( TXA2), a crucial physiological mediator. The systemic physiological consequence of this sustained TXA2 pathway interruption is a reduction in platelet aggregability, limiting the potential for thrombus formation. The secondary component, Magnesium Hydroxide, provides a non-systemic, localized chemical neutralization mechanism in the gastric lumen. This buffering action reduces the inherent acidic stress of the ASA molecule on the mucosal surface, mitigating this specific mechanism limitation and supporting the uninterrupted maintenance of the anti-thrombotic state.

Administration Scope and Principles

The combination drug Фазостабил is approved for oral administration as a film-coated tablet and is taken once daily for chronic usage. The therapeutic strategy requires continuous, long-term use for its intended purpose. The standard daily dose of the Acetylsalicylic Acid (ASA) component typically falls within the range of 75 mg to 160 mg.

Administration Conditions

For routine, continuous use, the tablet must be swallowed whole with an adequate amount of liquid and is generally taken after meals. The instruction to swallow the tablet whole is vital to the administration of the medicine, and the timing after a meal helps to manage digestive comfort. No specific dose adjustment is typically required for older adults, provided there are no concurrent severe hepatic or renal impairments, conditions which mandate caution during use.

Special Procedural Constraints

A procedural constraint is applied when the medicine is used at the start of treatment in an acute setting. If a higher initial dose, usually 150 mg to 450 mg of the ASA component, is administered for rapid onset, the tablet must be chewed or crushed before swallowing. This exception overrides the standard maintenance instruction and is specific to the initial loading procedure.

Connection to the Official Use Protocol

The official use protocol is structured to deliver a low, consistent daily dose via the oral route over an indefinite period for chronic prophylaxis. This structure is defined by the standard maintenance regimen, which prioritizes the integrity of the tablet for controlled delivery, and is strictly contrasted with the one-time acute loading procedure that requires immediate release of the active ingredients.

Research evidence / Overview of studies for Фазостабил

Evidence for Use in Preventing Recurrent Heart and Vascular Events (Secondary Prevention)

This area was evaluated in long-term Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These studies included adults who had already experienced a major vascular event, such as a heart attack (Myocardial Infarction) or certain types of stroke (Ischemic Stroke). Researchers explored patterns by monitoring and measuring the incidence of recurrent Major Adverse Cardiovascular Events (MACE) and other related outcomes over many years.

Pooled data and systematic reviews described patterns related to the monitored outcomes in the observed patient populations. Findings showed data patterns related to the rate of recurrent events. This evidence base contributes to the understanding of antiplatelet therapy over sustained periods, and the data contributes to the broader evidence landscape.

Evidence for Use After Vascular Procedures (Thrombotic Prophylaxis)

Clinical research has investigated antiplatelet therapy regimens in adults following specific vascular interventions. RCTs and comparative studies were conducted with patients who underwent procedures such as coronary stenting or bypass graft surgery. These studies monitored specific outcomes, including the occurrence of stent thrombosis and coronary reocclusion, to evaluate the response of the treated blood vessels.

The evidence contributes to understanding why an antiplatelet agent is observed in the strategy following intervention.

Evidence for Use in First-Time Event Prevention (Primary Prevention)

The primary prevention research area involves long-term RCTs that enrolled adults deemed to be at elevated cardiovascular risk but who had no prior history of an event. The findings from these primary prevention trials were mixed. While some studies reported findings related to MACE outcomes in specific, high-risk cohorts, other trials reported measurements that did not show patterns related to certain outcomes. In particular, studies exploring older adults showed mixed data patterns.

Long-Term Evidence and Follow-up Durations

Research exploring antiplatelet use for secondary prevention often involves long-term follow-up, with many studies structured around sustained observation periods over many years. While these long observation periods are essential, limited information is available to describe the very long-term outcomes in some of the newer patient cohorts.

Studies in Specific Patient Populations

Research has examined studies specifically designed to look at patient subgroups where the evidence may be less certain, such as older adults (aged 70 and above) and patients with diabetes. Research describes that outcomes for certain populations were observed to have varying patterns when measuring vascular events against other measured outcomes.

Gaps in the Research Record and Unanswered Questions

Despite the extensive research base, certain aspects of antiplatelet use remain uncertain. A key limitation is the inconsistency of findings across primary prevention trials. The evidence is limited for some patient subgroups. Research is ongoing to better characterize the patterns of outcomes across all risk categories. Furthermore, existing studies provide limited information about the specific long-term impact of the fixed-dose combination product (Фазостабил) versus the single ASA component.

Key Studies & References Aspirin and Magnesium Hydroxide Tablet (MedlinePlus Drug Information)

Common questions about Фазостабил (FAQ)

Q: What are the most commonly reported side effects listed in the official prescribing information for Фазостабил?

According to official product information, the most commonly reported side effects generally relate to the digestive system. These may include mild heartburn, nausea, vomiting, abdominal discomfort, and dyspepsia (upset stomach). The complete risk profile is available in the regulatory safety documents.

Q: Are there any officially mentioned signs of a serious side effect from Фазостабил that users should be aware of?

The regulatory label highlights certain serious signs that require professional medical attention. These include symptoms of internal bleeding, such as black, tarry, or bloody stools, or persistent vomiting. Signs of a serious allergic reaction, like swelling of the face, throat, or lips, are designated as events requiring immediate professional attention.

Q: How quickly do official sources suggest the therapeutic effect of Фазостабил begins?

Studies on the active component indicate that the antiplatelet effect is irreversible upon contact with blood platelets. For the standard maintenance regimen, this effect is sustained over time. Official documents note that for a rapid initial effect in an acute setting, a higher initial dose may be instructed to be chewed or crushed.

Q: What is the official risk classification of Фазостабил use during pregnancy or breastfeeding?

Official warnings indicate that the use of this medicine is generally contraindicated (must be avoided) during the third trimester of pregnancy. For breastfeeding, the magnesium hydroxide component is compatible, but the ASA component is secreted into breast milk, which is a factor assessed by healthcare providers.

Q: What official resources provide the most detailed patient safety information on Фазостабил?

The most detailed, regulatory-approved safety information for patients is typically contained within the Patient Information Leaflet (PIL) or Medication Guide supplied with the product. These documents are formally reviewed and regulated by government authorities like the EMA, FDA (DailyMed), or MHRA.

Q: Is a minor headache or mild nausea a listed possible side effect of Фазостабил?

Yes, official documents list both headache and mild nausea among the commonly reported or moderate side effects related to the salicylate component. These are classified within the full adverse reaction profile.

Q: Does the official guidance suggest Фазостабил has any known effects on weight or changes in appetite?

Official adverse reaction data indicates that loss of appetite is listed as a possible adverse effect of this medicine. However, significant changes in body weight are not typically listed in the standard regulatory safety documents.

Q: Does official guidance mention changes in mood or sleep as a possible effect of the drug?

Adverse reactions categorized under nervous system disorders sometimes include symptoms like restlessness and trouble sleeping (insomnia). Changes in mood are not explicitly detailed in the standard regulatory documentation.

Q: Are there specific food groups or drinks that should be avoided while taking Фазостабил?

Regulatory documents specifically state that co-administration with alcohol is associated with an officially documented increased risk of gastrointestinal bleeding. No specific non-alcoholic food groups are universally prohibited in the usage instructions.

Q: Is it known if Фазостабил can affect the effectiveness of hormonal birth control, based on available data?

Standard regulatory screening for interactions has not identified a major risk that would reduce the effectiveness of common hormonal contraceptives. However, acetylsalicylic acid may potentially affect the metabolism of certain hormonal components.

Q: Can Фазостабил affect the results of certain lab tests, such as those checking liver function?

The official label notes that periodic monitoring of certain blood parameters may be indicated, which can include liver function tests. Changes in lab results, such as an increase in bleeding time factors, have been noted in cases of high salicylate exposure.

Q: What general action is recommended if a user misses a single dose of Фазостабил?

The general guidance for a missed dose is to take it as soon as it is remembered, unless it is almost time for the next scheduled dose. If it is nearly time for the next dose, the missed dose should be skipped. Regulatory guidance advises against doubling the dose to compensate.

Q: Are there official warnings regarding Фазостабил and the ability to operate machinery or drive?

Official guidance sometimes includes a warning that certain adverse effects may potentially impair the ability to operate machinery or drive safely. Specifically, lightheadedness or dizziness are possible effects listed in the risk information.

Q: Is the active ingredient in Фазостабил considered a controlled or scheduled substance?

No, the active ingredients in this medicine, Acetylsalicylic Acid and Magnesium Hydroxide, are not classified as controlled or scheduled substances. This classification applies across major international regulatory bodies.

Q: What are the known non-active components (excipients) of Фазостабил?

The full list of non-active components, also known as excipients, is provided in the regulatory documents (such as the SmPC). These are the binding agents, coatings, and fillers used to create the final film-coated tablet formulation.

Q: Is there any official warning about increased sun sensitivity while taking Фазостабил?

No, increased sun sensitivity (photosensitivity) is not generally listed as a known or expected adverse reaction in the authoritative regulatory documents for this medicine.

Q: Does Фазостабил have any known effects on blood sugar levels, according to the warnings?

While salicylates can affect the metabolism of glucose, hypoglycemia (low blood sugar) is primarily noted as a possible symptom only in the context of severe salicylate intoxication or overdose.

Q: What is the general process for safely discontinuing Фазостабил treatment?

The official patient guidance indicates that because this is a continuous-use medicine, discontinuation should occur only under the direction of a healthcare professional.

Q: What is the half-life of Фазостабил's active ingredient, as described in pharmacokinetics data?

The pharmacokinetics data show that the active component Acetylsalicylic Acid (ASA) has a very short half-life of approximately 15 to 20 minutes as it is quickly converted. Its main metabolite, salicylate, is associated with the antiplatelet effect and has a longer half-life (2 to 4 hours at low doses).

Q: Does Фазостабил interact with herbal supplements or natural remedies like St. John's Wort?

Regulatory guidance generally recommends that a healthcare provider be aware of all concomitant products, including herbal supplements and natural remedies. Official information notes that certain combinations may carry an increased risk of bleeding.

Q: Do official documents describe any differences in the drug's effect between male and female patients?

Regulatory documents do not typically describe explicit differences in the drug’s intended effect between male and female patients. However, clinical trial data submitted in the regulatory dossier includes outcomes from both sexes.

Q: What is the recommended procedure for reporting adverse effects experienced with Фазостабил?

Regulatory documents detail the procedure for patients to report suspected adverse effects to their national regulatory authority. This process is usually managed through a dedicated program, such as the FDA MedWatch program or the MHRA Yellow Card Scheme.

Q: Is taking Фазостабил described as having any known risks while a person is attempting to conceive?

Regulatory documents note that the ASA component may impair female fertility. This potential factor is assessed by healthcare professionals when a patient is attempting conception.

Q: Does the medicine cause lightheadedness or affect balance according to the risk information?

Yes, lightheadedness (dizziness) is listed as a possible adverse effect in the official risk information. Official guidance sometimes includes warnings about how such effects may affect balance and the ability to operate machinery.

How to Store and Dispose of Фазостабил (Acetylsalicylic Acid/Magnesium Hydroxide)

The storage and disposal of Фазостабил must strictly adhere to the conditions outlined in the official regulatory labeling to maintain product stability.

Storage Requirements

• Temperature and Protection: Store tablets at controlled room temperature (20 C to 25 C). The medication must be kept in its original container and the container must be kept tightly closed to protect the active ingredient (ASA) from moisture and high heat.
• Child Safety: The product must be stored out of the reach and sight of children to prevent accidental ingestion.

Disposal Instructions

• Proper Disposal: Unused or expired tablets should be discarded according to local regulatory guidance or through an official drug take-back program.
• Wastewater Restriction: Do not dispose of the medication by flushing it down a toilet or pouring it into a drain, as this can pose an environmental risk.